Susquehanna International Group, LLP Terns Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$6.49 - $10.8 $63,602 - $105,840	-9,800 Reduced 3.79%	249,100 $2.08 Million
Q2 2024 Aug 15, 2024	BUY	$4.54 - $8.2 $715,050 - $1.29 Million	157,500 Added 155.33%	258,900 $1.76 Million
Q1 2024 May 07, 2024	BUY	$4.86 - $8.19 $273,618 - $461,097	56,300 Added 124.83%	101,400 $665,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $45,158 - $91,924	13,400 Added 42.27%	45,100 $292,000
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $77,080 - $140,220	16,400 Added 107.19%	31,700 $159,000
Q2 2023 Aug 11, 2023	BUY	$7.35 - $13.29 $112,455 - $203,337	15,300 New	15,300 $133,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.